| scholarly article | Q13442814 |
| P50 | author | Jeffrey Schlom | Q90227155 |
| P2093 | author name string | Claudia Palena | |
| Tyler J Curiel | |||
| Douglas W Grosenbach | |||
| Mary T Litzinger | |||
| Romaine Fernando | |||
| P2860 | cites work | Granulocyte/macrophage-colony stimulating factor produced by recombinant avian poxviruses enriches the regional lymph nodes with antigen-presenting cells and acts as an immunoadjuvant | Q73482867 |
| CD4+CD25+ regulatory T cells in patients with gastrointestinal malignancies: possible involvement of regulatory T cells in disease progression | Q73867902 | ||
| Vector-based vaccine/cytokine combination therapy to enhance induction of immune responses to a self-antigen and antitumor activity | Q78386134 | ||
| Increased populations of regulatory T cells in peripheral blood and tumor-infiltrating lymphocytes in patients with gastric and esophageal cancers | Q79157496 | ||
| Phase II trial of denileukin diftitox for relapsed/refractory T-cell non-Hodgkin lymphoma | Q79594581 | ||
| Depletion of CD4+CD25+ human regulatory T cells in vivo: kinetics of Treg depletion and alterations in immune functions in vivo and in vitro | Q79812085 | ||
| Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival | Q29547865 | ||
| Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-self | Q29619194 | ||
| Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells | Q34147162 | ||
| Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor alpha) monoclonal antibody. | Q34504134 | ||
| Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity | Q34505678 | ||
| Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. | Q34515741 | ||
| Increase of regulatory T cells in the peripheral blood of cancer patients. | Q34531138 | ||
| Inability of a fusion protein of IL-2 and diphtheria toxin (Denileukin Diftitox, DAB389IL-2, ONTAK) to eliminate regulatory T lymphocytes in patients with melanoma | Q34943798 | ||
| The peripheral generation of CD4+ CD25+ regulatory T cells | Q35154721 | ||
| Shared modes of protection against poxvirus infection by attenuated and conventional smallpox vaccine viruses | Q35234767 | ||
| Control of immune homeostasis by naturally arising regulatory CD4+ T cells | Q35589845 | ||
| T-cell priming in bone marrow: the potential for long-lasting protective anti-tumor immunity | Q35601732 | ||
| Denileukin diftitox: a concise clinical review | Q36066136 | ||
| The bone marrow: a nest for migratory memory T cells. | Q36174862 | ||
| Regulatory T cells in ovarian cancer: biology and therapeutic potential | Q36321305 | ||
| Gene expression and cytopathic effect of vaccinia virus inactivated by psoralen and long-wave UV light | Q39873004 | ||
| Systemic anti-CD25 monoclonal antibody administration safely enhances immunity in murine glioma without eliminating regulatory T cells | Q40252921 | ||
| IL-2 immunotoxin therapy modulates tumor-associated regulatory T cells and leads to lasting immune-mediated rejection of breast cancers in neu-transgenic mice | Q40265574 | ||
| The requirement of multimodal therapy (vaccine, local tumor radiation, and reduction of suppressor cells) to eliminate established tumors | Q40408782 | ||
| CD4+/CD25+ regulatory cells inhibit activation of tumor-primed CD4+ T cells with IFN-gamma-dependent antiangiogenic activity, as well as long-lasting tumor immunity elicited by peptide vaccination. | Q40614121 | ||
| Mice transgenic for human carcinoembryonic antigen as a model for immunotherapy | Q41051977 | ||
| Vaccine-based therapy directed against carcinoembryonic antigen demonstrates antitumor activity on spontaneous intestinal tumors in the absence of autoimmunity. | Q43958945 | ||
| Inhibition of CD4(+)25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide | Q45182740 | ||
| Cellular and humoral immunity against vaccinia virus infection of mice | Q45642985 | ||
| Antitumor Activity and Immune Responses Induced by a Recombinant Carcinoembryonic Antigen-Vaccinia Virus Vaccine | Q45865346 | ||
| CD25 expression is correlated with histological grade and response to denileukin diftitox in cutaneous T-cell lymphoma | Q46893226 | ||
| Confirmation of the activity of the interleukin-2 fusion toxin denileukin diftitox against chemorefractory chronic lymphocytic leukemia, including cases with chromosome 17p deletions and without detectable CD25 expression | Q47433363 | ||
| Phase I trial of a ligand fusion-protein (DAB389IL-2) in lymphomas expressing the receptor for interleukin-2. | Q53961036 | ||
| Expression of FOXP3 mRNA is not confined to CD4+CD25+ T regulatory cells in humans. | Q54645452 | ||
| Bone marrow is a reservoir for CD4+CD25+ regulatory T cells that traffic through CXCL12/CXCR4 signals. | Q54692947 | ||
| Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma | Q56904280 | ||
| CD4+CD25high regulatory cells in human peripheral blood | Q56905059 | ||
| Transient expression of FOXP3 in human activated nonregulatory CD4+ T cells | Q58234949 | ||
| Chemoimmunotherapy of Tumors: Cyclophosphamide Synergizes with Exosome Based Vaccines | Q58326930 | ||
| Synergy of vaccine strategies to amplify antigen-specific immune responses and antitumor effects | Q59489950 | ||
| Interleukin 2 (IL-2) receptor expression and sensitivity to diphteria fusion toxin DAB389IL-2 in cultured hematopoietic cells | Q71129142 | ||
| A triad of costimulatory molecules synergize to amplify T-cell activation | Q73229810 | ||
| P433 | issue | 9 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | vaccine | Q134808 |
| P304 | page(s) | 3192-3201 | |
| P577 | publication date | 2007-07-06 | |
| P1433 | published in | Blood | Q885070 |
| P1476 | title | IL-2 immunotoxin denileukin diftitox reduces regulatory T cells and enhances vaccine-mediated T-cell immunity | |
| P478 | volume | 110 |
| Q35157591 | A novel oxygen carrier "YQ23" suppresses the liver tumor metastasis by decreasing circulating endothelial progenitor cells and regulatory T cells. |
| Q37118188 | A paradigm shift in therapeutic vaccination of cancer patients: the need to apply therapeutic vaccination strategies in the preventive setting |
| Q38171325 | Adoptive immunotherapy of metastatic breast cancer: present and future |
| Q36988746 | Advancements in immune tolerance |
| Q38029122 | Advances in targeted therapeutic agents |
| Q35122843 | An increased abundance of tumor-infiltrating regulatory T cells is correlated with the progression and prognosis of pancreatic ductal adenocarcinoma |
| Q37276644 | Anti-CCR4 mAb selectively depletes effector-type FoxP3+CD4+ regulatory T cells, evoking antitumor immune responses in humans. |
| Q48480477 | Anti-GITR therapy promotes immunity against malignant glioma in a murine model. |
| Q35630407 | B7-H1-dependent sex-related differences in tumor immunity and immunotherapy responses. |
| Q40101895 | Bacterial Toxins for Cancer Therapy |
| Q38741294 | Biphasic Rapamycin Effects in Lymphoma and Carcinoma Treatment |
| Q37437275 | Blockade of MCP-1/CCR4 signaling-induced recruitment of activated regulatory cells evokes an antitumor immune response in head and neck squamous cell carcinoma |
| Q89724967 | CCL22 Signaling in the Tumor Environment |
| Q35015717 | CD73 has distinct roles in nonhematopoietic and hematopoietic cells to promote tumor growth in mice |
| Q37908998 | Cancer immunotherapy--revisited |
| Q36866158 | Cancer vaccines: Looking to the future |
| Q36368968 | Cancer vaccines: current directions and perspectives in prostate cancer |
| Q26745444 | Cellular Immune Responses and Immune Escape Mechanisms in Breast Cancer: Determinants of Immunotherapy |
| Q37132892 | Characterizing and optimizing immune responses to leukaemia antigens after allogeneic stem cell transplantation |
| Q35919850 | Chitosan as an adjuvant for a Helicobacter pylori therapeutic vaccine |
| Q85062314 | Circulating regulatory T cells (CD4+CD25+FOXP3+) decrease in breast cancer patients after vaccination with a modified MHC class II HER2/neu (AE37) peptide |
| Q37179415 | Combating immunosuppression in glioma |
| Q36828834 | Construction and Production of Foxp3-Fc (IgG) DNA Vaccine/Fusion Protein |
| Q36317185 | Current perspectives in prostate cancer vaccines |
| Q49997332 | DAB389IL-2 recombinant fusion toxin effect on lymphocyte- and macrophage-producing cytokine subpopulation cells in experimentally induced demyelinating disease in mice |
| Q45898692 | DAB389IL-2 suppresses autoimmune inflammation in the CNS and inhibits T cell-mediated lysis of glial target cells. |
| Q36755513 | Delicate balance among three types of T cells in concurrent regulation of tumor immunity |
| Q64268077 | Depleting T regulatory cells by targeting intracellular Foxp3 with a TCR mimic antibody |
| Q44933756 | Depleting regulatory T cells with arginine-rich, cell-penetrating, peptide-conjugated morpholino oligomer targeting FOXP3 inhibits regulatory T-cell function. |
| Q39756932 | Depletion of CD25⁺ T cells from hematopoietic stem cell grafts increases posttransplantation vaccine-induced immunity to neuroblastoma |
| Q37412327 | Depletion of endogenous tumor-associated regulatory T cells improves the efficacy of adoptive cytotoxic T-cell immunotherapy in murine acute myeloid leukemia |
| Q36787548 | Depletion of human regulatory T cells specifically enhances antigen-specific immune responses to cancer vaccines. |
| Q39093557 | Development of a diphtheria toxin-based recombinant porcine IL-2 fusion toxin for depleting porcine CD25+ cells |
| Q64988693 | Differential Regulation of T-cell mediated anti-tumor memory and cross-protection against the same tumor in lungs versus skin. |
| Q36016369 | Differential effects of denileukin diftitox IL-2 immunotoxin on NK and regulatory T cells in nonhuman primates |
| Q36043797 | Distinct effects of saracatinib on memory CD8+ T cell differentiation |
| Q49834009 | E7777 in Japanese patients with relapsed/refractory peripheral and cutaneous T-cell lymphoma: A phase 1 study. |
| Q26774934 | Effects of radiation on T regulatory cells in normal states and cancer: mechanisms and clinical implications |
| Q38809772 | Emerging Opportunities and Challenges in Cancer Immunotherapy. |
| Q39789605 | Engineered interleukin-2 antagonists for the inhibition of regulatory T cells |
| Q37620568 | Fallen angels or risen apes? A tale of the intricate complexities of imbalanced immune responses in the pathogenesis and progression of immune-mediated and viral cancers |
| Q43199366 | Forkhead box P3-positive regulatory T cells in immune surveillance and cancer |
| Q36915916 | FoxP3+CD4+ regulatory T cells play an important role in acute HIV-1 infection in humanized Rag2-/-gammaC-/- mice in vivo |
| Q37287162 | How tumours escape mass destruction |
| Q38669273 | Immune Therapy |
| Q37873928 | Immune therapy for ovarian cancer: promise and pitfalls |
| Q33878721 | Immunogenic and tolerogenic effects of the chimeric IL-2-diphtheria toxin cytocidal agent Ontak(®) on CD25(+) cells |
| Q37123810 | Immunoregulatory T cells: role and potential as a target in malignancy |
| Q35603131 | Immunosuppressive tumor microenvironment in cervical cancer patients |
| Q37829504 | Immunotherapeutic modulation of the suppressive liver and tumor microenvironments |
| Q41878129 | Immunotherapy as a strategy for the treatment of non-small-cell lung cancer |
| Q38390104 | Immunotherapy prospects in the treatment of lung cancer and mesothelioma |
| Q38000768 | Immunotherapy: a useful strategy to help combat multidrug resistance |
| Q35669197 | In situ vaccination against mycosis fungoides by intratumoral injection of a TLR9 agonist combined with radiation: a phase 1/2 study |
| Q37469869 | Inhibition of TGF-β1 signaling promotes central memory T cell differentiation |
| Q33629475 | Intensive chemotherapy for acute myeloid leukemia differentially affects circulating TC1, TH1, TH17 and TREG cells |
| Q38069640 | Ipilimumab in prostate cancer |
| Q48214652 | Lymphocytes in Placental Tissues: Immune Regulation and Translational Possibilities for Immunotherapy. |
| Q39196680 | Maternal T Regulatory Cell Depletion Impairs Embryo Implantation Which Can Be Corrected With Adoptive T Regulatory Cell Transfer |
| Q30513468 | Mitigating age-related immune dysfunction heightens the efficacy of tumor immunotherapy in aged mice. |
| Q37137430 | New Approaches to Immunotherapy for HPV Associated Cancers |
| Q36938731 | New insights into the role of the immune microenvironment in breast carcinoma. |
| Q26770391 | Novel immunotherapeutic approaches for the treatment of acute leukemia (myeloid and lymphoblastic) |
| Q39472057 | Ontak reduces the immunosuppressive tumor environment and enhances successful therapeutic vaccination in HER-2/neu-tolerant mice |
| Q38985262 | Ontogeny of Tumor-associated CD4+CD25+Foxp3+ T-regulatory Cells |
| Q26997338 | Optimal management of metastatic melanoma: current strategies and future directions |
| Q37236406 | Optimizing denileukin diftitox (Ontak) therapy |
| Q37259568 | PR1 vaccination in myeloid malignancies |
| Q34023724 | Pattern response of dendritic cells in the tumor microenvironment and breast cancer |
| Q37340462 | Peptide-based vaccines for cancer: realizing their potential |
| Q34099760 | Phase II trial of the regulatory T cell-depleting agent, denileukin diftitox, in patients with unresectable stage IV melanoma |
| Q37071100 | Phosphoantigen-activated V gamma 2V delta 2 T cells antagonize IL-2-induced CD4+CD25+Foxp3+ T regulatory cells in mycobacterial infection |
| Q33927418 | Pregnancy induces a fetal antigen-specific maternal T regulatory cell response that contributes to tolerance |
| Q60938672 | Principles of Immunotherapy: Implications for Treatment Strategies in Cancer and Infectious Diseases |
| Q37259642 | Promising particle-based vaccines in cancer therapy. |
| Q38089935 | Prostate cancer vaccines. |
| Q36273796 | Recent Advances in the Development of Antineoplastic Agents Derived from Natural Products |
| Q34238776 | Recombinant adenovirus IL-24-Bax promotes apoptosis of hepatocellular carcinoma cells in vitro and in vivo |
| Q37031308 | Regulatory B cells (B10 cells) and regulatory T cells have independent roles in controlling experimental autoimmune encephalomyelitis initiation and late-phase immunopathogenesis |
| Q37174953 | Regulatory T cells and treatment of cancer |
| Q91297827 | Regulatory T cells in cancer immunosuppression - implications for anticancer therapy |
| Q54329903 | Regulatory T-cells promote hepatitis B virus infection and hepatocellular carcinoma progression. |
| Q48265824 | Regulatory effects of dexamethasone on NK and T cell immunity. |
| Q37251467 | Suppression of murine allergic airway disease by IL-2:anti-IL-2 monoclonal antibody-induced regulatory T cells |
| Q40070517 | Suppressor Cell-Depleting Immunotherapy With Denileukin Diftitox is an Effective Host-Directed Therapy for Tuberculosis |
| Q37800935 | T regulatory cells in cancer: recent advances and therapeutic potential |
| Q34076526 | TGF-beta utilizes SMAD3 to inhibit CD16-mediated IFN-gamma production and antibody-dependent cellular cytotoxicity in human NK cells |
| Q43280097 | Targeted therapy to the IL-2R using diphtheria toxin and caspase-3 fusion proteins modulates Treg and ameliorates inflammatory colitis |
| Q38005176 | Targeting NKG2D in tumor surveillance |
| Q37595721 | Targeting Treg cells in situ: emerging expansion strategies for (CD4(+)CD25(+)) regulatory T cells |
| Q37952796 | Targeting the tumor microenvironment by immunotherapy: part 2. |
| Q33631986 | The role of regulatory T cells in cancer |
| Q27006663 | The role of regulatory T cells in cancer immunology |
| Q35894347 | Therapeutic cancer vaccines: current status and moving forward |
| Q28476803 | Therapeutic enhancement of protective immunity during experimental leishmaniasis |
| Q34527281 | Therapeutic opportunities for manipulating T(Reg) cells in autoimmunity and cancer |
| Q37270929 | Therapeutic vaccines for non-Hodgkin B-cell lymphoma. |
| Q37474385 | Timed sequential treatment with cyclophosphamide, doxorubicin, and an allogeneic granulocyte-macrophage colony-stimulating factor-secreting breast tumor vaccine: a chemotherapy dose-ranging factorial study of safety and immune activation |
| Q37724053 | Toll-like receptor 9 agonist enhances anti-tumor immunity and inhibits tumor-associated immunosuppressive cells numbers in a mouse cervical cancer model following recombinant lipoprotein therapy |
| Q64108546 | Turning the Tide Against Regulatory T Cells |
| Q34075574 | Up-regulation of Th17 cells may underlie inhibition of Treg development caused by immunization with activated syngeneic T cells |
| Q82980799 | Upfront denileukin diftitox as in vivo regulatory T-cell depletion in order to enhance vaccination effects in a canine allogeneic hematopoietic stem cell transplantation model |
| Q33734281 | Vaccines against human carcinomas: strategies to improve antitumor immune responses |
Search more.